A Registry Study to collect characteristics and outcomes from patients with Solid Tumors.
Not Applicable
- Conditions
- Health Condition 1: C801- Malignant (primary) neoplasm, unspecified
- Registration Number
- CTRI/2022/09/046041
- Lead Sponsor
- F HoffmannLa Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the
disease, at the enrolment date (informed consent date)
- Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date,
irrespective of the availability of test results
- Informed consent has been obtained from the patient or legally authorized representative,
as per local regulations
Exclusion Criteria
Patient has a prior (Disease free less than 5 years) or current diagnosis of hematological malignancy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - To provide a platform to support the design and conduct of clinical and epidemiological research <br/ ><br>- To develop an evidence-generation platform to better understand health outcomes and cancer care processes <br/ ><br>Timepoint: -facilitate identification of potential trial populations <br/ ><br>-identify, develop and qualify biomarkers, novel assessment tools and clinical endpoints <br/ ><br>-support the conduct of disease-modeling studies <br/ ><br>-identify the complex genomic landscape affecting the diagnosis and prognosis of solid tumor cancers and deepen the understanding of underlying biologic pathways <br/ ><br>
- Secondary Outcome Measures
Name Time Method To characterize the treatments and clinical course of solid tumor cancers in patients who <br/ ><br>have undergone NGS testingTimepoint: -identify the sub-populations that may best benefit from <br/ ><br>precision medicine tools